Inventiva S.A. Sponsored ADR (
NASDAQ:IVA -
Get Free Report) shot up 4.3% on Monday . The stock traded as high as $4.79 and last traded at $4.66. 21,740 shares changed hands during trading, a decline of 31% from the average session volume of 31,426 shares. The stock had previously closed at $4.47.
Inventiva Stock Performance
The company's fifty day moving average price is $3.47 and its two-hundred day moving average price is $3.28.
Hedge Funds Weigh In On Inventiva
An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 10,715 shares of the company's stock, valued at approximately $32,000. Institutional investors and hedge funds own 19.06% of the company's stock.
About Inventiva
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access